Skip to content.
About GPO   |   Newsroom/Media   |   Congressional Relations   |   Inspector General   |   Careers   |   Contact   |   askGPO   |   Help  

  FDsys > More Information
(Search string is required)

16-784 - Antrim Pharmaceuticals LLC v. Bio-Pharm, Inc.

Download Files


Document in Context
16-784 - Antrim Pharmaceuticals LLC v. Bio-Pharm, Inc.
April 19, 2018
PDF | More
ron, and otherwise denies the motion [dkt. no. 75]. The case is set for a status hearing on April 24, 2018 at 9:30 a.m. to set a trial date and discuss the possibility of settlement. (mk)MEMORANDUM OPINION AND ORDER signed by the Honorable Matthew F. Kennelly on 4/19/2018: For the reasons stated in the accompanying Memorandum Opinion and ORder, the Court denies Antrim's motion for summary judgment [dkt. no. 63]. The court grants Bio-Pharm's motion for summary judgment on Antrim's unjust enrichment claim (count 3 of Antrim's complaint), partially grants the motion on Antrim's breach of contract claim (count 1) to the extent the claim applies to ondanset